The FDA has officially approved the emergency use of the Pfizer coronavirus vaccine for certain populations.
The corresponding decision on booster vaccination was announced on Wednesday, September 22, on the official website of the FDA.
The American regulator amended the emergency use of the vaccine (EUA), according to which the third dose should be received in at least six months after full-fledged immunization will be able to: persons 65 years of age and older; persons 18-64 years of age with a high risk of severe COVID-19 disease; Persons 18-64 years old who frequently encounter SARS-CoV-2 in healthcare facilities or at work, at risk of contracting infection.
'' After reviewing the available scientific evidence and discussions by our advisory committee, the FDA amended the EUA for the Pfizer-BioNTech COVID vaccine to allow a booster dose for specific populations, such as healthcare workers. The pandemic is dynamic and evolving, and new data on the safety and efficacy of vaccines are coming in every day '', & ndash; said and. O. FDA chief Janet Woodcock.
She confirmed that the FDA intends to expand populations in the future as more data emerges on the safety and efficacy of COVID-19 vaccines.
The regulator's decision came after independent experts unanimously recommended last week to allow the emergency use of a booster dose for citizens over the age of 65 and those at risk of serious illness.